References

Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update

10.3748/wjg.v20.i23.7260 · 2014 · External reference

Resmetirom, the first FDA-approved drug for MASH: from drug discovery and action mechanisms to clinical trials

10.1007/s12272-025-01574-w · 2025 · External reference

Emerging insights into transforming growth factor β Smad signal in hepatic fibrogenesis

10.1136/gut.2005.088690 · 2007 · External reference

Oxidative stress and inflammation in hepatic diseases: therapeutic possibilities of N-acetylcysteine

10.3390/ijms161226225 · 2015 · External reference

Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines

10.1097/hep.0000000000000182 · 2023 · External reference

Farnesoid X receptor: from structure to function and its pharmacology in liver fibrosis

10.14336/ad.2023.0830 · 2024 · External reference

Targeting metabolic dysregulation for fibrosis therapy

10.1038/s41573-019-0040-5 · 2020 · External reference

Aging, ROS, and cellular senescence: a trilogy in the progression of liver fibrosis

10.1007/s10522-024-10153-3 · 2024 · External reference

Activation of GPR120 in podocytes ameliorates kidney fibrosis and inflammation in diabetic nephropathy

10.1038/s41401-020-00520-4 · 2021 · External reference

Senescence landscape in the liver following sepsis and senolytics as potential therapeutics

10.1111/acel.14354 · 2025 · External reference

Senotherapeutics: targeting senescence in idiopathic pulmonary fibrosis

10.1016/j.semcdb.2019.12.008 · 2020 · External reference

Senescence and tissue fibrosis: opportunities for therapeutic targeting

10.1016/j.molmed.2024.05.012 · 2024 · External reference

Liver fibrosis: mechanistic concepts and therapeutic perspectives

10.3390/cells9040875 · 2020 · External reference

Liver immunology and its role in inflammation and homeostasis

10.1038/cmi.2016.3 · 2016 · External reference

Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases

10.3390/ijms222413397 · 2021 · External reference

Structural mechanisms of NLRP3 inflammasome assembly and activation

10.1146/annurev-immunol-081022-021207 · 2023 · External reference

Activation of NLRP3 and AIM2 inflammasomes in Kupffer cells in hepatic ischemia/reperfusion

10.1111/febs.13123 · 2015 · External reference

The role of autophagy and NLRP3 inflammasome in liver fibrosis

10.1155/2020/7269150 · 2020 · External reference

Liuweiwuling tablets attenuate BDL-induced hepatic fibrosis via modulation of TGF-β/Smad and NF-κB signaling pathways

10.1016/j.jep.2017.08.029 · 2018 · External reference

Harnessing metabolism of hepatic macrophages to aid liver regeneration

10.1038/s41419-023-06066-7 · 2023 · External reference

Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunity

10.1016/j.coph.2009.04.008 · 2009 · External reference

Decreased Th1 cells and increased Th2 cells in peripheral blood are associated with idiopathic inflammatory myopathies patients with interstitial lung disease

10.1007/s10753-022-01747-5 · 2023 · External reference

TGF-β: the master regulator of fibrosis

10.1038/nrneph.2016.48 · 2016 · External reference

Dynamic crosstalk between HSCs and liver microenvironment: multicellular interactions in the regulation of liver fibrosis

10.3389/fcell.2025.1635763 · 2025 · External reference

Wnt/β-catenin signaling in liver development, homeostasis, and pathobiology

10.1146/annurev-pathol-020117-044010 · 2018 · External reference

Autophagy and senescence: the molecular mechanisms and implications in liver diseases

10.3390/ijms242316880 · 2023 · External reference

Mitochondria: a critical hub for hepatic stellate cells activation during chronic liver diseases

10.1016/j.hbpd.2021.04.010 · 2021 · External reference

GPR120: a critical role in adipogenesis, inflammation, and energy metabolism in adipose tissue

10.1007/s00018-017-2492-2 · 2017 · External reference

The role of GPR120 in diet induced obesity, mood dysregulation, and microglial function

2021 · External reference

Targeting hepatic stellate cell PD-L1 alters liver inflammation and fibrosis in CCl4 liver injury mouse model

10.1016/j.jcmgh.2025.101587 · 2025 · External reference

Progressive fibrosis in human MASLD is associated with spatially linked transcriptomic signatures of metabolic reprogramming and senescence

10.1016/j.jhepr.2025.101657 · 2025 · External reference

The power of plasticity—metabolic regulation of hepatic stellate cells

10.1016/j.cmet.2020.10.026 · 2021 · External reference

Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences

10.1016/j.jhep.2007.04.002 · 2007 · External reference

Fatty acids acutely enhance insulin-induced oxidative stress and cause insulin resistance by increasing mitochondrial reactive oxygen species (ROS) generation and nuclear factor-κB inhibitor (IκB) -nuclear factor-κB (NFκB) activation in rat muscle, in the absence of mitochondrial dysfunction

10.1007/s00125-011-2396-x · 2012 · External reference

Role of PNPLA3 in hepatic stellate cells and hepatic cellular crosstalk

10.1111/liv.16117 · 2025 · External reference

Loss of hepatic Mboat7 leads to liver fibrosis

10.1136/gutjnl-2020-320853 · 2021 · External reference

FOXC2-AS1/FOXC2 axis mediates matrix stiffness-induced trans-differentiation of hepatic stellate cells into fibrosis-promoting myofibroblasts

10.7150/ijbs.81581 · 2023 · External reference

Unresolved reference

2024 · External reference

MBOAT7 in liver and extrahepatic diseases

10.1111/liv.15706 · 2023 · External reference

MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD

10.1016/j.ebiom.2020.102866 · 2020 · External reference

Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease

10.1080/14728222.2026.2671694 · 2026 · External reference

Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells

10.1053/gast.2000.9365 · 2000 · External reference

Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats

10.1136/gut.2005.079194 · 2006 · External reference

Lysophosphatidic acid receptors: biochemical and clinical implications in different diseases

10.7150/jca.41841 · 2020 · External reference

Obeticholic acid: first global approval

10.1007/s40265-016-0616-x · 2016 · External reference

Targeting glutamine metabolism in hepatic stellate cells alleviates liver fibrosis

10.1038/s41419-022-05409-0 · 2022 · External reference

Methionine metabolism in chronic liver diseases: an update on molecular mechanism and therapeutic implication

10.1038/s41392-020-00349-7 · 2020 · External reference

Changes in glutathione content in liver diseases: an update

10.3390/antiox10030364 · 2021 · External reference

Epigenetic modification regulates tumor progression and metastasis through EMT (review)

10.3892/ijo.2022.5360 · 2022 · External reference

Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation

10.3945/ajcn.110.003483 · 2011 · External reference

Programmed cell death in hepatic fibrosis: current and perspectives

10.1038/s41420-023-01749-8 · 2023 · External reference

The multifaceted role of ferroptosis in liver disease

10.1038/s41418-022-00941-0 · 2022 · External reference

Metformin prevents PFKFB3-related aerobic glycolysis from enhancing collagen synthesis in lung fibroblasts by regulating AMPK/mTOR pathway

10.3892/etm.2021.10013 · 2021 · External reference

Mitochondria: a critical hub for hepatic stellate cells activation during chronic liver diseases

10.1016/j.hbpd.2021.04.010 · 2021 · External reference

A role for mitochondria in NLRP3 inflammasome activation

10.1038/nature09663 · 2011 · External reference

Macrophage polarization and its role in liver disease

10.3389/fimmu.2021.803037 · 2021 · External reference

Metabolic mechanisms orchestrated by Sirtuin family to modulate inflammatory responses

10.3389/fimmu.2024.1448535 · 2024 · External reference

Progress in nonalcoholic fatty liver disease: SIRT family regulates mitochondrial biogenesis

10.3390/biom12081079 · 2022 · External reference

Role of cellular senescence in hepatic diseases (review)

10.3892/ijmm.2025.5623 · 2025 · External reference

Senescence of activated stellate cells limits liver fibrosis

10.1016/j.cell.2008.06.049 · 2008 · External reference

Navigating the complex role of senescence in liver disease

10.1097/cm9.0000000000003439 · 2024 · External reference

Regulation of MnSOD enzymatic activity by Sirt3 connects the mitochondrial acetylome signaling networks to aging and carcinogenesis

10.1089/ars.2013.5482 · 2014 · External reference

Activation of the miR-34a/SIRT1/p53 signaling pathway contributes to the progress of liver fibrosis via inducing apoptosis in hepatocytes but not in HSCs

10.1371/journal.pone.0158657 · 2016 · External reference

New insights into AMPK, as a potential therapeutic target in metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis

10.4062/biomolther.2024.188 · 2025 · External reference

Inhibition of ASCT2 induces hepatic stellate cell senescence with modified proinflammatory secretome through an IL-1α/NF-κB feedback pathway to inhibit liver fibrosis

10.1016/j.apsb.2022.03.014 · 2022 · External reference

Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology

10.3978/j.issn.2304-3881.2014.11.03 · 2014 · External reference

SASP modulation for cellular rejuvenation and tissue homeostasis: therapeutic strategies and molecular insights

10.3390/cells14080608 · 2025 · External reference

Mechanobiology of YAP and TAZ in physiology and disease

10.1038/nrm.2017.87 · 2017 · External reference

Mechanosignaling via Integrins: pivotal players in liver fibrosis progression and therapy

10.3390/cells14040266 · 2025 · External reference

The role of YAP/TAZ activity in cancer metabolic reprogramming

10.1186/s12943-018-0882-1 · 2018 · External reference

The Hippo signaling pathway manipulates cellular senescence

10.3390/cells14010013 · 2025 · External reference

Flower-shaped lipid nanoparticles evade apolipoprotein E-mediated liver tropism for safe and enhanced cytokine-based cancer immunotherapy

10.1021/acsnano.5c11552 · 2025 · External reference

Transient hepatic reconstitution of trophic factors enhances aged immunity

10.1038/s41586-025-09873-4 · 2025 · External reference

Bile acids induce liver fibrosis through the NLRP3 inflammasome pathway and the mechanism of FXR inhibition of NLRP3 activation

10.1007/s12072-023-10610-0 · 2024 · External reference

Aspartate reduces liver inflammation and fibrosis by suppressing the NLRP3 inflammasome pathway via upregulating NS3TP1 expression

10.3390/jpm13030386 · 2023 · External reference